Excited to be at EACR 2024 in Rotterdam

Very honored by the recognition by my British colleagues.

@CD_AACR .

Very grateful to the ERC for granting the lab a third ERC advanced grant. With this new funding, we will study further the concept of deliberate overactivation of oncogenic signaling as a cancer treatment strategy.

RT @DiasMatheus101: Because age-old problems may require truly innovative interventions. We're thrilled to announce that we've taken the….

RT @EACRnews: When René Bernards @BernardsLabora1 says he’s excited about new data, it’s time to pay attention 🔥👀 Be among the first to see….

We discovered a major role for PP2A in controlling splicing, suggesting that PP2A inhibition sensitizes to checkpoint immunotherapy by generating neo antigens.

It’s combinations stupid! .

Kicking KRAS at AACR annual meeting Orlando

Thank you Mark Foundation for funding our research on vulnerabilities of senescent cancer cells.

Please check out our new publication in molecular oncology @MolOncology.

Today we posted on BioRXiv an exciting new approach to cancer therapy, in which drug resistance is associated with loss of tumor forming capacity!.

Pleased to join the board of directors of Lixte. LB-100 is a unique molecule that may help many cancer patients. I look forward to working with Lixte to bring this drug to the clinic by finding the right combinations and the right patient populations.

Excited to share our first findings using the Lixte PP2A inhibitor LB-100. A very exciting drug with unique mechanism of action.

Very proud to have been elected a member of the US National Academy of Science

We have identified factors that modulate the response to an interesting experimental cancer drug named indisulam.

The new lab neon sign. Kindly donated by Dr. Neto

Very pleased to collaborate with Heparegenix to find oncology applications for their MKK4 inhibitor

Pleased to work with Lixte on interesting new anti cancer drug.